Iambic Therapeutics (IAM) files S-1 to bring AI drug discovery public on Nasdaq
As seen on the 24/7 Wall St. homepage on September 21, 2026.
Iambic Therapeutics files S-1 for Nasdaq IPO
The AI drug discovery story is heading to public markets: Iambic Therapeutics filed its S-1 for a Nasdaq listing, with J.P. Morgan, Jefferies, BofA Securities and Citigroup leading the deal. Terms and deal size are not set yet, so the pricing amendment is the next thing to watch.
Continue ReadingShow less
Iambic Therapeutics has filed its S-1 with the SEC, formally launching the process to list on Nasdaq. The filing marks the first concrete step toward a public offering, though pricing terms and deal size have not yet been set.
J.P. Morgan, Jefferies, BofA Securities, and Citigroup are leading the offering, a syndicate that signals institutional appetite for the deal. A bookrunner lineup of that weight typically reflects underwriter confidence in generating demand from major funds.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
Iambic sits at the intersection of artificial intelligence and pharmaceutical drug discovery, a corner of biotech that has drawn significant investor attention as companies race to use machine learning to accelerate how new medicines are identified and developed. The S-1 filing puts that story directly in front of public market investors for the first time.
The next concrete event to track is the pricing amendment, which is when the company will set a share price range and disclose deal size. Until that amendment is filed, the financial scale of the offering remains open.